Baseline lupus factors influencing damage accrual in 99 lupus patients. Regression analysis
| OR | 95% confidence limits | p value | |
|---|---|---|---|
| New damage accrual | |||
| Intercept | 0.085 | - | 0.024 |
| Cytotoxics use (yes) | 12.64 | 0.88–182.47 | 0.062 |
| SLEDAI-2K | 1.130 | 0.996–1.28 | 0.057 |
| Anti-NSPA positivity | 17.604 | 1.13–273.52 | 0.040 |
| New damage accrual excluding anti-NSPA | |||
| Intercept | 0.20 | - | <0.001 |
| Cytotoxics use (yes) | 11.866 | 1.39–101.53 | 0.024 |
| SLEDAI-2K | 1.149 | 1.03–1.29 | 0.016 |
Candidate variables considered were: age, education, disease duration, SLEDAI-2K, SDI, cognitive deficit by Cambridge Neuropsychological Test Automated Battery (CANTAB), depression score of the Hospital Anxiety and Depression Scale (HAD), presence of antiphospholipid syndrome, prednisone use, cytotoxics use, anti-dsDNA positivity, anti-ribosomal P (anti-P) and anti-neuronal surface P antigen (anti-NSPA) antibodies positivity.